Premium
Natural leukocyte interferon‐α therapy in patients with chronic granulocytic leukemia who have antibody‐mediated resistance to treatment with recombinant interferon‐α
Author(s) -
Tefferi Ayalew,
Grendahl Darryl C.
Publication year - 1996
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199607)52:3<231::aid-ajh20>3.0.co;2-h
Subject(s) - medicine , alpha interferon , interferon alfa , immunology , recombinant dna , antibody , interferon , alpha (finance) , biology , gene , surgery , biochemistry , construct validity , patient satisfaction
Two patients with chronic‐phase chronic granulocytic leukemia initially responded to recombinant interferon α‐2a (rIFN‐α‐2a) but relapsed as a result of development of high‐titer neutralizing antibodies to rIFN‐α‐2a. Both patients were subsequently treated with natural leukocyte IFN‐α (IFN‐α‐n3), and one of the two patients achieved a durable second hematologic and cytogenetic remission. IFN‐α‐n3 may be considered for patients in whom antibody‐mediated resistance to rIFN‐α‐2a develops. © 1996 Wiley‐Liss, Inc.